Intervention Study On Total Ischemic Burden In Patients With Post-acute Coronary Syndrome With Xinnaoning Capsule

Objective:On the basis of guideline-guided medication therapy(GDMT),the effectiveness and safety of Xinnaoning capsules in treating antianginal symptoms in patients with post-acute coronary syndrome(ACS)was evaluated by observing the effect of the combination of Xinnaoning capsules on the total ischemic burden(TIB),weekly nitroglycerin withdrawal reduction rate and Seattle Angina Questionnaire(SAQ)score in post-ACS patients.Methods:The study in this thesis came from a large multicenter clinical study and our hospital is participating in this study as the lead sub-center.A central randomization system was employed to randomly assign a total of 60 patients with post-acute coronary syndrome to a control group(n=27)and an experimental group(n=33),all of them were enrolled in a randomized,double blind,placebo-controlled trial design.According to GDMT,the experimental group was given 3 Xinnaoning capsules and 3 placebo of Xinnaoning capsules in the control group,both taken at30 minutes after three meals.At the conclusion of the 12 th week of treatment,the TIB values,nitroglycerin withdrawal rate,and SAQ scores of the subjects were compared to those before treatment in order to assess the efficacy and security of the capsules.Results:(1)Before treatment,the baseline characteristics between the two groups were comparable(P>0.05).(2)After 12 weeks of treatment,the TIB in the two groups was significantly lower than that before treatment.(P<0.01),but there was no significant difference between the control and experimental groups(P>0.05).(3)The SAQ scores of the two groups were improved in all dimensions after treatment,and there was no statistical difference between the two groups(P>0.05),and no statistical difference between the two groups(P > 0.05).(4)The experimental group’s rate of nitroglycerine reduction after 12 weeks of therapy was 78.79%(26/33),and the control group’s 51.85%(14/27),with a statistical difference(Z=-2.297,P < 0.05).(5)No serious adverse reactions/events throughout the trial.Conclusion:In patients with post-acute coronary syndrome,the combination of Xinnaoning capsules on the basis of GDMT increased the weekly nitroglycerin withdrawal rate,reduced nitroglycerin dosage,improved severe myocardial ischemia and relieved severe angina symptoms,but had no significant effect on the reduction of TIB values and was not effective in improving patients’ survival quality.At the same time,no serious adverse effects/events were observed during the trial,demonstrating the safety and reliability of its clinical application.